Cystic fibrosis lung – Diagnostics – Overview of Information and Clinical Research

Diagnosing cystic fibrosis lung disease involves a combination of screening tests, genetic analysis, and specialized measurements that help doctors understand how the condition affects your breathing and overall health. Early and accurate diagnosis is essential for starting treatment and managing the disease effectively throughout life.

Introduction: When to Seek Diagnostics

Cystic fibrosis is a genetic condition that people are born with, though symptoms may not always appear immediately. Because of this, most children in many countries undergo routine newborn screening, which involves blood tests performed shortly after birth. This early testing looks for substances in the blood that may be elevated when cystic fibrosis is present, though it’s important to know that a positive newborn screen does not automatically mean your baby has the disease.^[8]

If a newborn screening test comes back positive, or if a child or adult shows signs that suggest cystic fibrosis, further diagnostic tests are needed to confirm the diagnosis. Common symptoms that should prompt testing include frequent lung infections such as recurrent pneumonia or bronchitis, persistent cough that produces thick mucus, difficulty breathing, wheezing, frequent sinus infections, slow growth in children, or failure to gain weight despite a good appetite. Adults with milder forms of the disease may experience chronic sinusitis, nasal polyps, unintended weight loss, or recurring digestive problems.^[3]

Anyone with a family history of cystic fibrosis or parents who are known carriers of the gene mutation should consider diagnostic testing if symptoms appear. Even without symptoms, genetic counseling and testing may be recommended for family members of people diagnosed with cystic fibrosis, as knowing your carrier status can be important for family planning decisions.^[8]

⚠️ Important

A positive newborn screening result does not confirm cystic fibrosis. Most babies who have a positive screening actually do not have the disease. The screening test looks at substances that can be elevated for other reasons, including premature birth. Always follow up with confirmatory testing before drawing any conclusions about your child’s health.

Classic Diagnostic Methods

The diagnosis of cystic fibrosis relies on several key tests that work together to provide a complete picture. The most important and widely used diagnostic test is called the sweat chloride test, which measures the amount of salt in a person’s perspiration. In people with cystic fibrosis, a faulty protein causes salt to become trapped inside cells, leading to unusually salty sweat. This test is considered the gold standard for diagnosing cystic fibrosis.^[3]

The sweat chloride test is a simple and painless procedure. A healthcare provider applies a colorless, odorless chemical to a small area of the skin, usually on the forearm or thigh. A weak electrical current is then used to stimulate the sweat glands, causing the skin to sweat. The sweat is collected on a special filter paper or gauze and sent to a laboratory for analysis. The entire process typically takes about an hour. If the test shows high levels of chloride in the sweat, it suggests cystic fibrosis, but the test should be repeated to confirm the results.^[8]

Genetic testing is another crucial diagnostic tool. Cystic fibrosis is caused by mutations in a gene called CFTR, which normally produces a protein that helps control the movement of salt and water in and out of cells. There are thousands of different mutations that can affect this gene, though some are more common than others. Genetic testing involves analyzing a blood sample or cells from inside the cheek to look for these mutations. Finding two CFTR gene mutations confirms a diagnosis of cystic fibrosis.^[3]

The pattern of inheritance is called autosomal recessive, which means a child must inherit one mutated gene from each parent to develop the disease. If a child inherits only one mutated gene, they become a carrier but do not have cystic fibrosis themselves. In the United States, approximately one in 20 people are carriers of a CF gene mutation. When both parents are carriers, there is a 50 percent chance they will pass the mutated gene to their child, and if both parents pass on the mutation, the child will have cystic fibrosis.^[8]

Once cystic fibrosis is suspected or confirmed, doctors use additional tests to understand how the disease is affecting the lungs and other organs. Pulmonary function tests measure how well the lungs are working by checking how much air you can breathe in and out, and how quickly you can do so. These tests help doctors track lung function over time and adjust treatment as needed. You simply breathe into a machine that records various measurements about your breathing capacity and airflow.^[12]

Imaging tests like chest X-rays or computed tomography (CT) scans create pictures of the lungs and airways. These images can reveal mucus buildup, infections, scarring, or other damage caused by cystic fibrosis. A chest X-ray is often one of the first imaging tests performed, while CT scans provide more detailed images and may be used when doctors need a closer look at specific areas of concern.^[12]

Doctors also analyze samples of mucus from the lungs, either through sputum collection (where you cough up mucus into a container) or bronchoalveolar lavage (where a flexible tube is inserted into the airways to collect fluid). These samples are sent to a laboratory to identify which bacteria or other germs are present. This information is vital because people with cystic fibrosis are prone to specific types of lung infections, and knowing which organism is causing the infection helps doctors choose the most effective antibiotics.^[12]

A less common but sometimes necessary test is called nasal potential difference measurement. This test measures the electrical activity of cells lining the nose, which can be abnormal in people with cystic fibrosis. While not routinely used, it can be helpful in cases where sweat testing and genetic testing do not provide clear answers.^[12]

For newborns, the initial screening typically involves measuring a substance called immunoreactive trypsinogen (IRT) in the blood. Trypsinogen is an enzyme produced by the pancreas, and levels are often elevated in newborns with cystic fibrosis. However, elevated IRT alone does not confirm the disease, which is why follow-up testing with sweat chloride tests and genetic testing is essential.^[12]

In infants, a contrast barium enema may be used if there are concerns about a specific intestinal complication called meconium ileus, which occurs when thick, sticky stool blocks the intestines shortly after birth. This imaging test uses a special dye to make the intestines visible on X-rays.^[12]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or approaches for managing cystic fibrosis. To participate in a clinical trial, patients must meet specific criteria established by the researchers. These criteria often include diagnostic tests that confirm not only the presence of cystic fibrosis but also specific characteristics of the disease.

One of the most important qualifying factors for many clinical trials is the type of CFTR gene mutation a person carries. Different mutations affect the CFTR protein in different ways, and some experimental treatments are designed to work only with certain mutation types. Therefore, detailed genetic testing and genotyping are essential to determine eligibility. Researchers categorize CFTR mutations into different classes based on how they affect protein production or function, and trial enrollment may be limited to people with mutations in specific classes.^[3]

Pulmonary function tests are frequently used as entry criteria for clinical trials. Many studies require participants to have lung function within a certain range, measured by tests that assess how much air you can forcefully exhale in one second. This helps researchers study treatments in people with similar disease severity. For example, a trial testing a new medication to improve lung function might only accept participants whose lung function has declined to a specific level.

Sweat chloride testing may also be required for clinical trial enrollment, especially for studies evaluating medications designed to correct the underlying defect in the CFTR protein. Changes in sweat chloride levels can indicate whether a treatment is successfully improving the function of the defective protein, so baseline measurements are important for comparison.

Some clinical trials require evidence of specific complications or symptoms, which means additional diagnostic procedures may be necessary. For instance, a study focused on treating chronic lung infections might require cultures of sputum or bronchoalveolar lavage fluid to confirm the presence of particular bacteria. Similarly, trials testing treatments for digestive complications may require tests that measure pancreatic enzyme levels or nutritional status.

Imaging tests such as CT scans may be used to assess the extent of lung damage or to identify structural abnormalities like bronchiectasis, a condition where the airways become widened and damaged. The presence or severity of bronchiectasis, as seen on imaging, can be a factor in determining trial eligibility.

⚠️ Important

Clinical trial participation requires meeting specific criteria that go beyond simply having a cystic fibrosis diagnosis. Your genetic mutation type, lung function levels, infection status, and other health factors all play a role in determining eligibility. If you are interested in joining a trial, discuss with your cystic fibrosis care team which tests you may need to qualify and whether a particular trial is a good match for your situation.

Blood tests may be required to check for CF-related complications such as diabetes or nutritional deficiencies. Many people with cystic fibrosis develop a form of diabetes called cystic fibrosis-related diabetes, which occurs when damage to the pancreas affects insulin production. Blood glucose testing and other metabolic assessments may be part of trial screening.

Finally, some trials require documentation of a patient’s treatment history, including a record of medications taken, hospitalizations, and responses to previous therapies. This information helps researchers understand whether a new treatment offers benefits beyond standard care.

Enrolling in a clinical trial can provide access to cutting-edge therapies and contribute to advancing knowledge about cystic fibrosis. However, the rigorous diagnostic requirements ensure that participants are appropriate candidates for the study and that the results will be meaningful for understanding how new treatments work.

Prognosis and Survival Rate

Prognosis

The outlook for people with cystic fibrosis has improved dramatically over recent decades, though the disease remains a serious, lifelong condition that requires ongoing management. The prognosis depends on many factors, including how early the disease is diagnosed, the specific type of gene mutations involved, the severity of lung and digestive complications, and how well a person follows their treatment plan. Classic cystic fibrosis, which affects multiple organs and is usually diagnosed in early childhood, tends to be more severe than atypical cystic fibrosis, a milder form that may only affect one organ and is often diagnosed later in life.^[3]

The most serious complications of cystic fibrosis involve the lungs, where thick, sticky mucus leads to frequent infections and progressive damage. Over time, this can result in conditions like bronchiectasis, where the airways become permanently widened and scarred. Some people experience sudden worsening of symptoms called pulmonary exacerbations, which may require hospitalization. Other complications include collapsed lung, allergic reactions to fungi, pancreatitis, diabetes, and malnutrition.^[14]

While there is currently no cure for cystic fibrosis, advances in treatment have made it possible for many people to live well into adulthood. More than half of individuals living with cystic fibrosis today are adults, highlighting how far medical care has come. Quality of life and survival depend heavily on early diagnosis through newborn screening, access to specialized care at cystic fibrosis centers with multidisciplinary teams, strict adherence to treatments including airway clearance techniques and medications, proper nutrition, and regular monitoring to prevent or manage complications.^[14]

Survival rate

Survival rates for cystic fibrosis have improved significantly thanks to better screening, treatments, and comprehensive care. In the past, cystic fibrosis was considered a childhood disease that typically led to death before adulthood. Today, the predicted median age of survival is approximately 37 years, and this number continues to rise. Children born between 2019 and 2023 with cystic fibrosis are expected to live an average of 61 years. On average, half of babies born in 2023 with cystic fibrosis are projected to reach the age of 68 or older.^[4]

Nearly 40,000 children and adults in the United States, and more than 100,000 worldwide, are now living with cystic fibrosis. These numbers reflect the substantial progress made in understanding and managing the disease. However, it is important to recognize that individual outcomes vary widely based on factors such as the specific genetic mutations present, the severity of organ involvement, access to specialized care, and how well treatments are followed.^[4]

Despite these improvements, most people with cystic fibrosis do not live as long as those without the condition, and the disease becomes more severe over time. Continued research into new therapies, including treatments that target the underlying genetic defect, offers hope for further extending and improving the lives of people with cystic fibrosis.^[3]

#1 Clinical Trials Search in Europe